Navigation Links
NewGen Therapeutics Reports Potent Anticancer Activity for Targeted Brain Cancer Drug, NT-113
Date:11/25/2013

MENLO PARK, Calif., Nov. 25, 2013 /PRNewswire/ -- NewGen Therapeutics, Inc. today announced that preclinical data demonstrate a high therapeutic potential for the company's targeted therapeutic candidate for brain cancer, NT-113. Data from in vivo studies of the experimental drug demonstrated potent anticancer activity and improved survival in a mouse intracranial xenograft model implanted with both EGFR (epidermal growth factor)-amplified and EGFRvIII-mutated glioblastoma cell lines.

(Logo: http://photos.prnewswire.com/prnh/20130408/SF90357LOGO)

The findings were presented by scientists from the Brain Tumor Research Center at the University of California, San Francisco (UCSF) as an oral podium presentation entitled "Preclinical evaluation of NT-113, a novel erbB inhibitor optimized for CNS (central nervous system) biodistribution" at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology, on November 24, 2013 in San Francisco, California.

"Given NT-113's robust anti-cancer activity in multiple intracranial human glioblastoma xenograft studies, excellent pharmacokinetics and very high capacity to cross the blood brain barrier, we plan to initially explore this potential targeted medicine for patients with glioblastoma and non-small cell lung cancer with brain metastases," said Harry D. Pedersen, chief executive officer of NewGen Therapeutics. "EGFR alterations drive many solid tumors to grow and spread.  Overexpression and/or mutations of EGFR occur in 40-60% of glioblastoma patients and 40-80% of non-small cell lung cancer patients, most of whom eventually develop brain metastases. Focusing on patients with EGFR over-expression or mutations in these studies should result in higher response rates, improved survival and more rapid approval timelines."

Mr. Pedersen commented that NewGen planned to initiate Phase 1 studies with NT-113 in early 2015.

About NewGen
NewGen Therapeutics is a privately held pharmaceutical company developing patient-targeted cancer drugs that are designed to overcome limitations of currently available therapies. The company's pipeline includes multiple programs with novel small molecule drug leads against clinically important targets, each addressed to significant medical needs. NT-113, a potent irreversible pan-erbB inhibitor, is the company's most advanced program and has demonstrated anti-cancer activity in several cancer xenograft studies, including glioblastoma, non-small cell lung, breast and gastric cancers.  For more information, please visit our website at http://www.newgenther.com.


'/>"/>
SOURCE NewGen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. NewGen Therapeutics Presents Data on NT-113, A Novel Pan-ErbB Inhibitor, at American Association of Cancer Research
2. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
3. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
4. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
5. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
6. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
7. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
8. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
9. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
10. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
11. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... Oct. 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Software and Consulting, LLC , and named its founder ... based in Tennessee , will operate ... expands EnvoyHealth,s service offerings for health care partners to ... "In an interoperable world, technology ...
(Date:10/2/2017)... 2017 The Rebound mobile app is poised to ... the tide of prescription drug addiction. The app empowers users ... and stepping down their dosage in a safe, controlled manner ... 2017; the first 100,000 people to sign up will enjoy ... ...
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
Breaking Medicine Technology:
(Date:10/13/2017)... IL (PRWEB) , ... October 13, 2017 , ... ... which established the certification process to promote standards of excellence for the field ... Symposium, scheduled for March 22 – 25, 2018 in Orlando, Florida at the ...
(Date:10/13/2017)... ... 2017 , ... Many families have long-term insurance that covers care for a ... waiver for care if the client has a cognitive impairment diagnosis. , “What ... is often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... be giving viewers the lowdown on sciatica in a new episode of "Success ... focuses on current events and innovation and investigates each subject in-depth with passion ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized health ... expanded their existing home health joint venture through an agreement, effective October 1, ... joint venture home health company with Asante, delivering clinically integrated care, for the ...
Breaking Medicine News(10 mins):